Evidence map›Paper›PMID 33021488›Full record

ArticleJMIR mental health2020

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial.

Jamie Webb, Sarrah Peerbux, Peter Smittenaar, Sarim Siddiqui, Yusuf Sherwani, Maroof Ahmed, Hannah MacRae, Hannah Puri, Sangita Bhalla, Azeem Majeed

Open access · goldAbstract read
In one paragraph

Article in JMIR mental health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Economic Impact of an Employer-Sponsored Integrated Digital Intervention Targeting Substance Use Disorders: Return on Investment Analysis.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2025
    Article
  14. Digitalizing Specialist Smoking Cessation Support in Pregnancy: Views of Pregnant Smokers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Jamie WebbDigital Therapeutics Inc, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-1020-0773
Sarrah PeerbuxImperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-5560-0749
Peter SmittenaarDigital Therapeutics Inc, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-7017-3439
Sarim SiddiquiDigital Therapeutics Inc, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-4909-316X
Yusuf SherwaniDigital Therapeutics Inc, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-2027-9550
Maroof AhmedDigital Therapeutics Inc, San Francisco, CA, United States.ORCID https://orcid.org/0000-0003-1057-6583
Hannah MacRaeDigital Therapeutics Inc, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-9060-6561
Hannah PuriDigital Therapeutics Inc, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-0521-5241
Sangita BhallaDigital Therapeutics Inc, San Francisco, CA, United States.ORCID https://orcid.org/0000-0001-9742-0367
Azeem MajeedImperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-2357-9858
Rapt Therapeutics (United States) · USImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

objectiveOur objective was to test the preliminary effectiveness of Quit Genius, a novel digital therapeutic intervention for smoking cessation.

methodsA 2-arm, single-blinded, parallel-group randomized controlled trial design was used. Participants were recruited via referrals from primary care practices and social media advertisements in the United Kingdom. A total of 556 adult smokers (aged 18 years or older) smoking at least 5 cigarettes a day for the past year were recruited. Of these, 530 were included for the final analysis. Participants were randomized to one of 2 interventions. Treatment consisted of a digital therapeutic intervention for smoking cessation consisting of a smartphone app delivering cognitive behavioral therapy content, one-to-one coaching, craving tools, and tracking capabilities. The control intervention was very brief advice along the Ask, Advise, Act model. All participants were offered nicotine replacement therapy for 3 months. Participants in a random half of each arm were pseudorandomly assigned a carbon monoxide device for biochemical verification. Outcomes were self-reported via phone or online. The primary outcome was self-reported 7-day point prevalence abstinence at 4 weeks post quit date.

resultsA total of 556 participants were randomized (treatment: n=277; control: n=279). The intention-to-treat analysis included 530 participants (n=265 in each arm; 11 excluded for randomization before trial registration and 15 for protocol violations at baseline visit). By the quit date (an average of 16 days after randomization), 89.1% (236/265) of those in the treatment arm were still actively engaged. At the time of the primary outcome, 74.0% (196/265) of participants were still engaging with the app. At 4 weeks post quit date, 44.5% (118/265) of participants in the treatment arm had not smoked in the preceding 7 days compared with 28.7% (76/265) in the control group (risk ratio 1.55, 95% CI 1.23-1.96; P<.001; intention-to-treat, n=530). Self-reported 7-day abstinence agreed with carbon monoxide measurement (carbon monoxide <10 ppm) in 96% of cases (80/83) where carbon monoxide readings were available. No harmful effects of the intervention were observed.

conclusionsThe Quit Genius digital therapeutic intervention is a superior treatment in achieving smoking cessation 4 weeks post quit date compared with very brief advice.

trial registrationInternational Standard Randomized Controlled Trial Number (ISRCTN) 65853476; https://www.isrctn.com/ISRCTN65853476.

Indexed as

appcessationdigitalmHealthmobilemobile phonerandomized controlled trialsmoking

Identifiers

PMID33021488
PMCPMC7576529
OpenAlexW3091147373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.